SPDR Pharmac

OTR Therapeutics, co-funded by Lilly Asia Ventures, announced the completion of a $100 million Series A financing

Eli Lilly provides an additional $25 million in funding to Adverum Biotechnologies as per acquisition agreement.

Axsome Therapeutics Inc. CEO Disposes of Company Common Stock

Jazz Pharmaceuticals Director O'Keefe Sold 603 Shares of Company Stock

Merck Raises $8 Billion Through Multiple Tranches of Notes

FDA Approves Merck's New Parasitic Drug for Cattle

Sina Finance In-depth Report: How Weight-Loss Drugs Propelled Eli Lilly to a Trillion-Dollar Pharmaceutical Giant

FDA Senior Official Richard Pazdur's Retirement Sparks Industry Attention

ISPE Announces Keynote Speakers and Technical Themes for the 2026 Future Facilities Conference

Kennedy Capital Management Reduced Johnson & Johnson Holdings in Q2

Kennedy Capital Management Reduces Holdings in Eli Lilly

Lilly plans to present positive Phase III clinical data for Pirtobrutinib in the treatment of CLL/SLL at the ASH Annual Meeting.

BMO Raises Eli Lilly's Target Price to $1200

Panagora Asset Management Inc. reduces holdings in Merck & Co., Inc. stock

BMO Capital raises Eli Lilly's price target to $1,200, maintaining an 'Outperform' rating.

Eli Lilly and Company Scheduled for Quarterly Dividend Payout

Eli Lilly to Present Multiple Abstracts at the 2025 American Society of Hematology (ASH) Annual Meeting

Merck's stock rises 1.3% after Goldman Sachs upgrades target price

Nuvation Bio Inc.'s Chief Medical Officer Liu Dongfang sells company common stock

Eli Lilly Launches $40 Million Collaboration with Indiana University for Clinical Trials and Life Science Research

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Hoyne Bancorp

Tradr 2X Long ASTS Daily ETF

AXSM

Tabuteau Herriot, Chairman of Axsome Therapeutics Inc, sold 79,973 shares worth $11.6M, as disclosed in a Form 4 filed with the SEC. The transaction was executed under a prearranged trading plan (10b5-1). Ending holdings are 7,351,729 shares. The Washington Service offers insider trading analysis and data services.

Reuters

Axsome Therap

Chmn Tabuteau Sells 79,973 ($11.6M) Of Axsome Therapeutics Inc [AXSM]

Herriot Tabuteau, CEO and Director of Axsome Therapeutics Inc., reported the disposal of common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system, with Ref. ID: 0001193125-25-308354, dated December 04, 2025.

Axsome Therapeutics CEO Herriot Tabuteau Reports Disposal of Common Shares

NVDA

AAPL

Following significant recent losses, the stock market is in need of a strong rebound. Investors are advised to keep a close eye on Nvidia, Apple, and Eli Lilly. Dow Jones Futures have seen a promising rise, while Novo Nordisk has experienced a significant dip. This update emphasizes the importance of monitoring these key companies for potential shifts in the market.

Unusual Whales

NVIDIA

Eli Lilly

Apple

Dow Jones futures up, Novo Nordisk down. Market recovery needed after recent losses. Nvidia, Apple, Eli Lilly in focus.

JAZZ

Director Kenneth W. O'Keefe of Jazz Pharmaceuticals Plc surrendered 603 shares back to the company to cover option exercise costs and/or tax liabilities. The transaction was filed with the SEC on December 4, 2025, at a price of $173.07 per share, totaling $104,361. O'Keefe's ending holdings are 30,256 shares, with 25,811 direct and 4,445 indirect.

Jazz Pharma

Dir O'Keefe Surrenders 603 Of Jazz Pharmaceuticals Plc [JAZZ]

HALO

Health-care stocks fell sharply as traders shifted to rate-sensitive sectors. Halozyme secured a preliminary injunction against Merck & Co. in a patent dispute over Keytruda in Germany. The Trump administration's biomedical innovation goals face challenges within the FDA, amid infighting and staff turnover influenced by Robert F. Kennedy Jr.'s policy changes.

marketscreener

Merck

Halozyme Therap

Health Care Down Sharply on Rotation to Rate-Sensitive Sectors -- Health Care Roundup

ULTA

Small-cap stocks are nearing all-time highs as Dow Jones futures surge. Eli Lilly's stock is at a critical level, while Ulta Beauty reports strong earnings. Robinhood leads new stock purchases, and five stocks are in buy zones, indicating promising investment opportunities.

Ulta Beauty

Small caps approach all-time highs, Eli Lilly at key level, 5 stocks in buy zones as Dow Jones futures surge. Ulta Beauty posts strong earnings. Robinhood leads new buys.

Merck & Co., Inc. has raised $8 billion through a multi-tranche notes offering, including various debt instruments with maturities ranging from 2029 to 2065. The offering closed on December 4, 2025, under the company's shelf registration statement filed with the SEC. This capital raising effort involves several series of notes with varying interest rates and maturities.

Merck Raises $8 Billion in Multi-Tranche Notes Offering

AMGN

ABBV

Amgen Inc. shares fell 1.52% to $340.16 on Thursday, underperforming compared to competitors. The S&P 500 Index rose 0.11%, while the Dow Jones Industrial Average fell 0.07%. Amgen's stock ended a two-day winning streak and closed 1.80% below its 52-week high. Competitors' performances varied: Johnson & Johnson fell 1.39%, Pfizer rose 0.51%, and AbbVie fell 0.66%. Trading volume was 3.4 million, above the 50-day average of 2.5 million.

Dow Jones

Johnson & Johnson

Amgen

Abbvie

Amgen Inc. Stock Underperforms Thursday When Compared To Competitors

Eli Lilly & Co. (LLY) shares fell 1.85% to $1,014.49 on Thursday, marking the sixth consecutive day of losses. The stock underperformed compared to competitors like Johnson & Johnson, Pfizer, and AbbVie. It closed 8.77% below its 52-week high. Trading volume was slightly below the 50-day average. The S&P 500 rose 0.11%, while the Dow Jones fell 0.07%.

Eli Lilly & Co. Stock Underperforms Thursday When Compared To Competitors

Scotiabank raised its target price for Merck & Co., Inc. (NYSE:MRK) from $105.00 to $120.00, giving the stock a "sector outperform" rating. This suggests a potential upside of 18.98% from the current price. Other analysts have mixed ratings, with some upgrading and others downgrading their ratings. Merck's recent earnings report showed a revenue increase of 3.7% year-over-year and an EPS of $2.58, beating estimates. The company has set its FY 2025 guidance at 8.930-8.980 EPS.

Market Beat

Scotiabank Issues Positive Forecast for Merck & Co., Inc. (NYSE:MRK) Stock Price

VKTX

Viking Therapeutics (VKTX) shares rose 11.17% due to excitement in obesity treatment and positive clinical trial developments. The company completed patient enrollment for its Phase 3 VANQUISH-1 trial ahead of schedule, attracting more participants than expected. This momentum is part of a broader interest in GLP-1 and obesity drug developers, with major players like Eli Lilly and Novo Nordisk competing in the market. VKTX shows strong short-term momentum, trading above its 20-day and 200-day SMA, indicating a bullish trend.

fidelity

Novo Nordisk AS

Viking Therap

What's Up With The Jump In Viking Therapeutics Stock?

MarketBeat highlights Eli Lilly, Novo Nordisk, and Bristol Myers Squibb as top pharmaceutical stocks to watch. These companies offer exposure to healthcare innovation but carry risks related to clinical trials, regulatory approvals, and sector-specific activities. Despite Eli Lilly's moderate buy rating, analysts suggest other stocks may offer better returns.

Bristol Myers Squibb

Top Pharmaceutical Stocks To Add to Your Watchlist - December 4th

NUVB

Nuvation Bio Inc. (NYSE:NUVB) saw its stock rise by 12.05% to $8.37 following positive phase 2 clinical trial results for Safusidenib, a treatment for a type of brain tumor.

Nuvation Bio

Nuvation Bio (NUVB) bounces back 12% on impressive clinical trial result

Merck says Exzolt Cattle-CA1 to be available by prescription in Q1 2026

Merck says Exzolt Cattle-CA1 to be available by prescription in Q1 2026

U.S. Senate Democrats are pushing for a vote next week on a three-year extension of Affordable Care Act subsidies set to expire this month. They need 13 Republican votes to overcome a filibuster. Republicans seek policy reforms like income caps and Hyde Amendment restrictions. House Speaker Mike Johnson has not committed to a vote on any Senate healthcare legislation. The deadline for insurance plan changes is December 15.

US Senate Democrats seek vote on three-year extension of healthcare subsidies